Finance ❯ Stock Market ❯ Public Companies ❯ NASDAQ

Gossamer Bio, Inc.

Gossamer Bio Investors Sought to Lead Lawsuit After Seralutinib Trial Failure

Plaintiff firms are recruiting investors over claims Gossamer misled them about its PAH trial.

Law Firm Reminds Investors of Lead-Plaintiff Deadlines in Suits Targeting Gossamer, New Era, Medpace and Stellantis